pmc logo image
Logo of curroncolJournal URL: http://www.current-oncology.com
Journal List > Curr Oncol > v.15(5); Oct 2008

Formats:
Curr Oncol. 2008 October; 15(5): 204–205.
PMCID: PMC2582514
Copyright 2008 Multimed Inc.
Anal cancer and human papillomaviruses in heterosexual men
A. Nyitray, MS
Richard J. Ablin, PhD, Research Professor of Immuno-biology and Pathology, University of Arizona College of Medicine and the Arizona Cancer Center, Tucson, Arizona, U.S.A. and Phil Gold, PhD MD, Professor of Medicine, Physiology, and Oncology, McGill University, Montreal, Quebec, Canada, Section Editors
Correspondence to: Alan Nyitray, University of Arizona, Mel and Enid Zuckerman College of Public Health, Tucson, Arizona, U.S.A., E-mail: nyitray/at/email.arizona.edu
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BACKGROUND
Human papillomavirus (hpv) causes a variety of anogenital cancers and is considered the primary cause of anal canal cancer 1,2. Anal cancer is a rare disease: a total of 4650 diagnoses of anal carcinoma and 690 deaths were expected in the United States in 2007, with approximately 40% of the diagnoses and deaths being expected to occur in men. Other than cervical cancer, anal cancer was expected to be the most commonly diagnosed anogenital hpv-associated cancer in 2007 3.
PARALLELS BETWEEN CERVICAL AND ANAL CANCER
Although anal cancer is less common than cervical cancer, its incidence in U.S. men is increasing, to 1.6 per 100,000 in 2005 from 0.6 per 100,000 in 1973. During the same period, the incidence of cervical cancer in women decreased 4. An increasing incidence of anal cancer noted also in Europe 5 is likely attributable to increased anal disease occurring in immunocompromised people and in men who have sex with men (msm) 6–8. Indeed, the risk ratio of observed to expected anal cancers has been reported to be 37.9 [95% confidence interval (ci): 33.0 to 43.4] in men with hiv, 59.5 (95% ci: 51.5 to 68.4) in homosexual men with hiv, and 5.9 (95% ci: 2.7 to 11.2) in heterosexual male injection drug users with hiv 9. Appropriately, anal cancer research to date has focused on these populations. However, it is a concern that healthy heterosexual men constitute 90% of the male population and that virtually no research regarding anal hpv has targeted them. Epidemiologic research also indicates that heterosexual men with hiv, even in the absence of receptive anal intercourse, may have a high prevalence of precancerous anal lesions associated with hpv10. Finally, a clearer understanding of the risks associated with anal hpv in heterosexual men may provide important contrasts that will help clarify the picture of anal hpv-related morbidity and mortality in other populations.
As in cervical cancer, most anal cancers are associated with oncogenic hpv types 16 and 18 2,11. Given an identical pathogen and similarity of the tissue (including a transformation zone in the anal canal that is bounded on each side by squamous and columnar epithelium 12), hpv-induced carcinogenesis leading to cervical cancer is comparable to the process that leads to anal canal cancer. However, although the deployment of a preventive vaccine for hpv infection and cervical dysplasia reflects important progress in preventing cases of cervical cancer 13, policymakers do not have the information needed to make informed decisions about vaccine delivery to prevent anal cancer. The necessary information will hopefully come from ongoing hpv vaccine studies in men and from modelling efforts that can provide quantitative insight into the economic and public health effects of the vaccine. However, accurate modeling of vaccine cost-effectiveness with regard to anal hpv in men requires more natural history data 14,15, and there are no such studies, published or ongoing, of anal hpv in heterosexual men. Indeed, few studies have estimated anal hpv prevalence in heterosexual men.
PREVALENCE OF ANAL HPV
In a community-based study of anal hpv in 222 asymptomatic heterosexual men, we recently estimated anal hpv prevalence at 16.6% for the anal canal and 21.3% for the perianal region. Of men with anal hpv, one third harboured an oncogenic hpv type. Also, men with anal hpv were more than twice as likely as men with no anal hpv to be in their 20s [odds ratio (or): 2.41; 95% ci: 1.05 to 5.55] 16. Two other smaller studies of exclusively heterosexual men from a clinic for sexually transmitted infections and of partners of women with confirmed hpv estimated anal hpv prevalences of 1.2% 17 and 8% 18 respectively. The higher prevalence found in our sample may result from the use of more sensitive test kits for hpv dna detection.
These prevalence data are a first step in understanding anal hpv in heterosexual men, but they need to be confirmed in other populations of heterosexual men. We are currently conducting a three-country anal hpv prevalence study with men recruited by a collaborative team led by Dr. Anna Giuliano of the H. Lee Moffitt Cancer Center and Research Institute. Follow-up longitudinal studies are needed, because these prevalence data can blend (and obscure) critical natural history characteristics of anal hpv that are needed to inform prevention strategies.
SUMMARY
Little is known about anal hpv in men—and especially in heterosexual men. Against this backdrop of scarce data, the incidence of anal cancer has risen considerably. Although knowledge about anal hpv in msm has advanced in the last decade (important advances, given the increased rate of anal cancer in msm), the much greater number of heterosexual men and the lack of epidemiologic data describing anal hpv in heterosexual men should prompt additional research in this area.
Footnotes
This scientific paper is the work of Mr. Nyitray and was made possible through the support of Merck Frosst Canada Ltd. The opinions and information contained herein are those of the author and do not necessarily reflect the views or opinions of Merck Frosst Canada Ltd.
REFERENCES
1. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80. [PubMed]
2. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350–8. [PubMed]
3. Ries L, Melbert D, Krapcho M, et al. seer Cancer Statistics Review, 1975–2004. BethesdaD: National Cancer Institute; 2007.
4. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci), Surveillance, Epidemiology, and End Results (seer) Program. Cancer Incidence: seer Registries Limited-Use. Bethesda: Cancer Statistics Branch, NCI; [Available online at: seer.cancer.gov/data/metadata.html; cited June 11, 2007]
5. Frisch M, Melbye M, Møller H. Trends in incidence of anal cancer in Denmark. BMJ. 1993;306:419–22. [PubMed]
6. Bower M, Powles T, Newsom–Davis T, et al. hiv-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004;37:1563–5. [PubMed]
7. Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the hiv epidemic. J Acquir Immune Defic Syndr. 2005;40:451–5. [PubMed]
8. Cress RD, Holly EA. Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973–1999. Prev Med. 2003;36:555–60. [PubMed]
9. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus–associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–10. [PubMed]
10. Wilkin TJ, Palmer S, Brudney KF, Chiasson MA, Wright TC. Anal intraepithelial neoplasia in heterosexual and homosexual hiv-positive men with access to antiretroviral therapy. J Infect Dis. 2004;190:1685–91. [PubMed]
11. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001;61:1934–40. [PubMed]
12. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127–34. [PubMed]
13. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase ii efficacy trial. Lancet Oncol. 2005;6:271–8. [PubMed]
14. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41. [PubMed]
15. Goldhaber–Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007;5:11. [PubMed]
16. Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis. 2008;197:1676–84. [PubMed]
17. Van Doornum GJ, Prins M, Juffermans LH, et al. Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourin Med. 1994;70:240–6. [PubMed]
18. Nicolau SM, Camargo CG, Stávale JN, et al. Human papillomavirus dna detection in male sexual partners of women with genital human papillomavirus infection. Urology. 2005;65:251–5. [PubMed]
Articles from Current Oncology are provided here courtesy of
Multimed Inc.

PubMed articles by these authors
See more articles cited in this paragraph
See more articles cited in this paragraph
See more articles cited in this paragraph
See more articles cited in this paragraph